Quanterix

194 articles with Quanterix

• Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance

  8/8/2022

  Quanterix Corporation, a company expanding the limits of exploration with ultrasensitive biomarker detection, announced operating results for the three months ended June 30, 2022.

• Quanterix Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors

  8/8/2022

  Quanterix Corporation, a company expanding the limits of exploration with ultrasensitive biomarker detection, announced that E. Kevin Hrusovsky is stepping down as Executive Chairman of its Board of Directors.

• Quanterix Announces Appointment of Karen A. Flynn to Board of Directors

  6/6/2022

  Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn, Senior Vice President and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), has been appointed to Quanterix’ Board of Directors effective June 6, 2022.

• Quanterix Corporation Releases Operating Results for First Quarter 2022

  5/10/2022

  Quanterix reports continued revenue growth as it scales to support transformational advances in neurology research.

• Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022

  5/3/2022

  Quanterix Corporation today announced that it will release its financial results for first quarter 2022 before the start of trading on May 10, 2022.

• Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis

  4/22/2022

  Quanterix Corporation today announced that its Simoa® neurofilament light chain (NfL) plasma test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration.

• Quanterix’ Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients

  4/4/2022

  Quanterix’ Simoa ® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients.

• Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2021

  3/1/2022

  Quanterix Corporation today announced financial results for the fourth quarter and twelve months ending December 31, 2021.

• Quanterix Announces New Agreements with Lilly to Advance Alzheimer’s Disease Diagnosis and Treatment

  3/1/2022

  Quanterix Corporation today announced it has entered into a collaboration with Eli Lilly and Company (Lilly) to advance the diagnosis, monitoring and treatment of Alzheimer’s disease.

• Quanterix Announces Executive Leadership Succession Plan

  3/1/2022

  Masoud Toloue, President of Quanterix and Diagnostics, to Become CEO and Join Board of Directors.

• Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

  2/23/2022

  Quanterix Corporation today announced that it will release its financial results for fourth quarter 2021 before the start of trading on Tuesday, March 1, 2022.

• Quanterix to Participate in the SVB Leerink Global Healthcare Conference

  2/9/2022

  Quanterix Corporation announced that its Chairman and Chief Executive Officer, Kevin Hrusovsky, will present virtually at the SVB Leerink Global Healthcare Conference on Feb. 16 at 4:20 p.m., EST.

• UK Dementia Research Institute Biomarker Factory Powers Alzheimer’s Disease Breakthroughs with Quanterix Simoa® Technology

  2/7/2022

  Quanterix Corporation announced its Simoa® technology is powering groundbreaking neurodegenerative disease research at the recently launched UK Dementia Research Institute Biomarker Factory, where Professor Henrik Zetterberg is leading an effort to develop the next generation of ultrasensitive tests to increase our knowledge of diseases such as Alzheimer’s and other dementias at the earliest possible stages of detection.

• Quanterix Corporation Releases Operating Results for Third Quarter of 2021

  11/4/2021

  Quanterix Corporation today announced financial results for the three months ending September 30, 2021.

• 

  Cassava’s Positive New Alzheimer’s Data Meets Lukewarm Reception

  9/23/2021

  Cassava Sciences announced top-line results Wednesday from a 12-month interim analysis of its Alzheimer’s drug candidate simufilam.

• Quanterix Hosts Webinar with Leading Pathologist from Emory Medical Laboratories

  9/20/2021

  Quanterix Corporation presented a webinar on Sept. 16, 2021, hosted by Kevin Hrusovsky, Quanterix Chairman and Chief Executive Officer

• 

  FDA Grants Key Approvals to Potential Rare and Serious Disease Treatments

  9/15/2021

  FDA has been actively greenlighting a number of efforts over the last few days to push therapies for rare or serious diseases that have largely unmet medical needs. Here's a look.

• Quanterix Receives Label Expansion on Emergency Use Authorization for COVID Antigen Test

  9/13/2021

  Quanterix Corporation announced that the Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) label for its Simoa® SARS-CoV-2 N Protein Antigen Test to include testing with nasal swab and saliva samples, and for asymptomatic serial testing with nasal swab samples.

• Quanterix to Host Webinar with Leading Pathologist from Emory Medical Laboratories: “COVID-19 Testing in a Residential University Setting: Implementation, Insights, and Learnings”

  9/10/2021

  Quanterix Corporation today announced a webinar hosted by Kevin Hrusovsky, Quanterix Chairman and Chief Executive Officer, with leading pathologist Dr. John Roback, M.D., Ph.D.

• Quanterix Releases Statement

  8/27/2021

  Quanterix Corporation today released the following statement in response to news reports related to Cassava Sciences. Cassava previously engaged Quanterix’ Accelerator laboratory to perform sample testing based on blinded samples provided by Cassava. Quanterix or its employees did not interpret the test results or or prepare the data charts presented by Cassava at the Alzheimer’s Association International Conference (AAIC) in July 2021 or otherwise.